You are here

Imatinib Mesylate Discontinuation in Patients With CML Treated with Front-Line IM Therapy and Achieved Complete Molecular Response

Ho-Young Yhim, Na-Ri Lee, Eun-Kee Song, Chang-Yeol Yim, So Yeon Jeon, Seunghwan Shin, Jeong-A Kim, Hee Sun Kim, Eun Hae Cho, Jae-Yong Kwak Division of Hematology/Oncology, Department of Internal Medicine, Republic of Korea.



Abstract


The aims were to investigate the feasibility of imatinib mesylate (IM) discontinuation in chronic myeloid leukemia patients who were initially treated with IM and achieved complete molecular response (CMR). Fourteen patients were included. Ten were relapsed within 9.5months after discontinuation of IM. All 7 patients with high Sokal risk were relapsed. The probability of CMR persistence at 1-year was 28.6%.
All relapsed patients were still responsive to IM. A high Sokal risk and delayed acquisition of CMR were associated with relapse. IM discontinuation in patients achieved CMR after treatment with front-line IM might be feasible. Further studies are warranted.
Read full text here...
www.lrjournal.com/article/SO145-2126(12)00071-9/fulltext